Viridian posts first Lumvoa revenue but net loss widens

What happened

Viridian reported first-quarter net product revenue from Lumvoa after its Q3 launch, with over 100 patients on therapy and progress in market access. Its Q3 net loss widened from a year earlier as selling and administrative costs rose to support commercial activities, while research and development expenses fell.

Confirmed

Global impact / market context

Lumvoa revenue shows the launch has begun generating sales, but the larger quarterly loss indicates those sales have not yet offset Viridian’s overall costs. Higher selling and administrative spending supports commercial activity, so revenue growth and spending control will shape how quickly the product contributes to financial results.

Analyst inference

The supplied article reports an average analyst rating of “buy,” with 17 strong-buy or buy recommendations and no holds or sells. That positive positioning contrasts with a wider loss, making evidence of sustained Lumvoa sales and the cost of commercial expansion relevant to investor expectations.

Confirmed

What to watch

1. Track whether Lumvoa revenue rises beyond its first-quarter launch level and whether the number of patients on therapy grows, as these indicate commercial uptake. Analyst inference
2. Watch selling and administrative costs alongside Lumvoa sales: continued spending to support the launch could limit how much revenue narrows the loss. Analyst inference
3. Viridian plans to submit a biologics license application for elegrobart in thyroid eye disease in Q1 2027; watch for progress toward that filing. Confirmed

Evidence

• Original source link unavailable